Murali Prahalad, Ph. D. is the president and CEO of Epic Sciences. Dr. Prahalad has more than 14 years of experience in technology and life science companies. Prior to joining Epic Sciences, he was formerly vice president of Corporate Strategy at Life Technologies, where he helped shape the organic and inorganic investment priorities across Life Technologies' research tools, clinical diagnostic and applied market portfolios. Dr. Prahalad was with Life Technologies since 2005, where he held multiple positions of increasing responsibility. His experience at Life Technologies ranged from mergers and acquisitions to inlicensing and general management, where he led large businesses that spanned genomics to cell biology. As a general manager, he had to grow revenue and profit by building stronger teams, driving innovation and managing operations for both consumable and instrument portfolios. Portfolios of note and relevance to Epic Sciences included Molecular Probes®, transfection (Lipofectamine®), custom primers and research antibodies in addition to Life Technologies imaging instrumentation (FLoID®, TALI®, Countess®) and flow cytometry platforms (Attune®). Prior to Life Technologies, he was vice president of Business Development at Sequenom, Inc. He is also proficient and literate in several languages including Japanese, French and Kannada. Dr. Prahalad received a Ph.D. in biochemistry and molecular pharmacology and an M.S. in medical sciences from Harvard University, and he received his B.S. with honors in cellular and molecular biology and economics from the University of Michigan.
Pascal Bamford, Ph.D. is the vice president, product development at Epic Sciences. Dr. Bamford obtained his Ph.D. from the University of Queensland, Australia, and researched how cancer-associated changes in DNA structure, detectable in digital images, could be used to automate the process of distinguishing cervical cancer from normal cells. His early career was spent developing automated cytology imaging systems at CSSIP in Australia in collaboration with Accumed International of Chicago. He subsequently took on the role of director of Imaging at MonoGen, where he developed an all-digital, microscopy-based, cervical cancer screening product, which was recognized as the first “killer app” for the field of digital pathology. For the past five years at Ventana-Roche, Dr. Bamford has held various roles of increasing responsibility in research, digital pathology and assay development, working on fluorescence multiplexing imaging systems and driving several bright field IHC algorithm CE-IVD and 510(k) clearances. Most recently Dr. Bamford led the detection reagent development of Ventana’s next generation staining platform. He is the author of six patents and more than 18 scientific publications.
Mr. Ryan Dittamore is the vice president, translational research and clinical affairs at Epic Sciences. Mr. Dittamore is a recognized molecular diagnostics leader with a broad range of scientific, medical, and business experience in developing and commercializing cancer diagnostics. Mr. Dittamore is leading translational research and clinical affairs activities for Epic Sciences to develop clinical validity and utility for new products to address critical unmet medical needs in oncology. This effort includes initiation and execution of numerous oncology clinical trials with top academic and government institutes. Mr. Dittamore’s background includes a diverse set of roles spanning over 18 years in the diagnostic and life science industries inclusive of research, product development, marketing, business development, sales and global channel management. Previous to his tenure at Epic Sciences, he was director of medical innovation and disease lead for genitourinary (GU) cancers at Ventana Medical Systems (Roche Tissue Diagnostics). During his time there he lead translational research, product development and marketing efforts for GU medical value products. His work has led to numerous novel abstracts, publications and patents towards improving patient outcomes. He holds a B.S. in biology, from University of Oregon and an MBA from University of Massachusetts, Amherst.
Ian Miller is Vice President and General Counsel at Epic Sciences. Mr. Miller holds a B.S. in Biochemistry & Cellular Biology from UC San Diego, and a J.D. from Duke University, School of Law and has over 18 years of experience in the technology and life sciences industries. Prior to joining Epic Sciences, Mr. Miller was an associate at Covington & Burling, with a practice focused on complex commercial transactions for life sciences companies. His legal practice has also included extensive experience in both intellectual property and litigation matters.